Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies – Takeda, Ovid Therapeutics, and Ganaxolone

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies - Takeda, Ovid Therapeutics, and Ganaxolone

“Delveinsight Business Research LLP”
DelveInsight’s “Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the CDKL5 Deficiency Disorder Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: An Overview

CDKL5 Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by changes (mutations) in the CDKL5 gene. CDD has been classified as a DEE because the genetic change causes both epileptic activities as well as severe impairment of development. Previously known as serine/threonine-protein kinase 9 (STK9), CDKL5, and mutations in this gene were first identified as disease-causing in 2004.

The hallmarks of CDD are the onset of seizures at a very early age, (usually about 3 months but can be as early as the first week of life) and severe neurodevelopmental delay impacting cognitive, motor, speech, and visual function. CDD can manifest in a broad range of clinical severity and is often associated with other symptoms such as gastrointestinal and sleep disturbances.

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Key Facts

  • As per the “National Organization for Rare Disorders (NORD),” CDKL5 mutations have been identified in many ethnic groups, with more females than males being reported with an approximate ratio of 4:1.

  • As per DelveInsight’s estimation, there were 16,511 prevalent cases of CDKL5 in the 7MM in 2020. Out of this, the maximum cases were contributed by the US (6,138 in 2020).

  • As per the study titled “CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy” conducted by Jakimiec et al. (2020): The CDKL5 mutation is diagnosed in 8–16% of girls with early-onset epilepsy. However, in the population with early infantile epileptic encephalopathy (EEIE), this mutation was confirmed in 28% of girls and only in 5.4% of boys.

  • As per the US National Library of Medicine, more than 1,000 cases have been reported worldwide.

  • In EU-5, Germany has the highest number of diagnosed cases, i.e., 602 followed by Italy with 394 cases and France with 282 cases. While Spain has the least number of cases with 193 in 2020.

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market size in the 7MM was found to be USD 6.54 Million in 2020. The market size is expected to increase during the forecast period owing to the extensive research and development activities of pharmaceutical companies and the expected launch of therapies such as TAK-935/OV935 (Takeda and Ovid Therapeutics) and Ganaxolone (Marinus Pharmaceuticals).

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted CDKL5 Deficiency Disorder market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.

The report gives a thorough detail of the CDKL5 Deficiency Disorder market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Epidemiology

The epidemiology section covers insights about the historical and current CDKL5 Deficiency Disorder patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Epidemiology Segmentation

  • Total Prevalent Population of CDKL5 Deficiency Disorder

  • Gender-specific Prevalence of CDKL5 Deficiency Disorder

  • Clinical Manifestation Specific Prevalence of CDKL5 Deficiency Disorder

  • Diagnosed and Treatable Prevalence of CDKL5 Deficiency Disorder

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CDKL5 Deficiency Disorder market or expected to get launched in the market during the study period. The analysis covers CDKL5 Deficiency Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the CDKL5 Deficiency Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Therapeutics Analysis

The dynamics of the CDKL5 Deficiency Disorder (CDD) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies.

Some of the key companies in the Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market include:

  • Takeda 

  • Ovid Therapeutics

  • Ganaxolone

And many others

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Therapies covered in the report include:

  • Ganaxolone – Ganaxolone, developed by Marinus Pharmaceuticals, is an allosteric modulator of GABAA receptors acting through binding sites which are distinct from the benzodiazepine binding site. It has activity in a broad range of animal models of epilepsy.

  • TAK-935/OV935 – Soticlestat (TAK-935/OV935) is a potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) being investigated as an anti-epileptic drug (AED).

And many more

Get More Detailed Insights into the Emerging Therapies & Key Companies:- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Therapeutics Landscape

Table of Content

1. Key Insights

2. Executive Summary 

3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Competitive Intelligence Analysis

4. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Overview at a Glance

5. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Disease Background and Overview

6. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Patient Journey

7. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology and Patient Population

8. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Unmet Needs

10. Key Endpoints of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment

11. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Marketed Products

12. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Emerging Therapies

13. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Outlook (7 major markets)

16. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Access and Reimbursement Overview

17. KOL Views on the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market.

18. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Drivers

19. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/